Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Depreciation and Depletion (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Depreciation and Depletion for 4 consecutive years, with $44599.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation and Depletion rose 10.2% to $44599.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $175636.0, a 38.54% decrease, with the full-year FY2024 number at $162332.0, down 30.35% from a year prior.
  • Depreciation and Depletion was $44599.0 for Q3 2025 at bioAffinity Technologies, roughly flat from $44468.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $166264.0 in Q4 2023 to a low of $800.0 in Q3 2022.
  • A 4-year average of $37292.5 and a median of $40243.0 in 2024 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: soared 5536.88% in 2023, then crashed 74.25% in 2024.
  • bioAffinity Technologies' Depreciation and Depletion stood at $7382.0 in 2022, then skyrocketed by 2152.29% to $166264.0 in 2023, then plummeted by 74.25% to $42806.0 in 2024, then grew by 4.19% to $44599.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Depreciation and Depletion are $44599.0 (Q3 2025), $44468.0 (Q2 2025), and $43763.0 (Q1 2025).